A PATIENT-SIDE TECHNIQUE FOR REAL-TIME MEASUREMENT OF ACETYLCHOLINESTERASE ACTIVITY DURING MONITORING OF EPTASTIGMINE TREATMENT

被引:13
作者
MOSCA, A
ONELLI, E
ROSTI, E
PALEARI, R
LUZZANA, M
IMBIMBO, BP
机构
[1] ITBA,MILAN,ITALY
[2] CNR,MILAN,ITALY
[3] MEDIOLANUM FARMACEUT,MILAN,ITALY
[4] UNIV MILAN,DEPT SCI & BIOMED TECHNOL,MILAN,ITALY
关键词
ACETYLCHOLINESTERASE; ALZHEIMERS DISEASE; EPTASTIGMINE; HEPTYLPHYSOSTIGMINE; CHOLINESTERASE INHIBITORS;
D O I
10.1097/00007691-199506000-00004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Rapid and reliable measurement of acetylcholinesterase (AChE) activity is of crucial importance to the pharmacodynamic monitoring of anticholinesterase drugs. A new assay has been developed to measure AChE from 10 mu l samples of capillary blood. AChE activity was calculated from the change in pH of the reaction medium caused by the hydrolysis of acetylcholine and measured with a highly sensitive differential pH apparatus (CL-10, Eurochem, Rome, Italy). Interference by butyrylcholinesterase was eliminated by a specific inhibitor, quinidine sulfate. The assay lasts 1 min. The coefficient of variation (CV) for replicated measurements was 2.8% (3267 U/L, n = 33). Linearity ranged from 0 to 10,000 U/L. The correlation coefficient between the new technique and Ellman's colorimetric method on washed erythrocytes was r = 0.987 (y = 1.299x - 63, n = 29). The correlation coefficient between assays on capillary and venous samples was r = 0.979 (y = 0.974x + 174, n = 47). A cross-laboratory validation study was performed in 10 centers using glycerol-stabilized hemolysates with normal and reduced AChE activity. Samples were assayed in triplicate. The within- and between-laboratory CVs for samples with normal AChE activity (6,018 U/L) were 2.2 and 8.1%, respectively. The new method was applied to a double-blind, placebo-controlled multicenter study of eptastigmine in Alzheimer patients and proved to be a simple, noninvasive, rapid, and reliable method for pharmacodynamic monitoring of this drug.
引用
收藏
页码:230 / 238
页数:9
相关论文
共 31 条
[1]  
Brufani M., Marta M., Pomponi M., Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia, Eur J Bio-Chem, 157, pp. 115-120, (1986)
[2]  
De Sarno P., Pomponi M., Giacobini E., Tang X.C., Williams E., The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat, Neuro-Chem Res, 14, pp. 971-977, (1989)
[3]  
Brufani M., Castellano C., Marta M., Et al., A long-lasting cholinesterase inhibitor affecting neural and behavioral processes, Pharm Biochem Behav, 26, pp. 625-629, (1987)
[4]  
Perry E.K., The cholinergic hypothesis—ten years on, Br Med Bull, 42, pp. 63-69, (1986)
[5]  
Mohs R.C., Davis B.M., Johns C.A., Oral physostigmine treatment of patients with Alzheimer’s disease, Am J Psychiatry, 142, pp. 28-33, (1985)
[6]  
Thai L.J., Physostigmine in Alzheimer’s disease, Cholinergic Basis for Alzheimer's therapy, pp. 209-215, (1991)
[7]  
Becker R.E., Moriearty P., Unni L., The second generation of cholinesterase inhibitors: Clinical and pharmacological effects, Cholinergic Basis for Alzheimer’s Therapy, pp. 263-296, (1991)
[8]  
Herold M.L., Constanzer M.L., Matuszewski B.K., Determination of picogram levels of heptylphysostigmine in human plasma using high-performance liquid chromatography with fluorescence detection, J Chromatogr, 581, pp. 227-236, (1992)
[9]  
Zecca L., Radice D., Mosca A., Pagella P.G., Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection, J Chromatogr Biomed Appl, 615, pp. 169-173, (1993)
[10]  
Luzzana M., Dossi G., Mosca A., Measurement of glucose in plasma by a differential pH technique, Clin Chem, 29, pp. 80-85, (1983)